DE60005471D1 - EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose - Google Patents

EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose

Info

Publication number
DE60005471D1
DE60005471D1 DE60005471T DE60005471T DE60005471D1 DE 60005471 D1 DE60005471 D1 DE 60005471D1 DE 60005471 T DE60005471 T DE 60005471T DE 60005471 T DE60005471 T DE 60005471T DE 60005471 D1 DE60005471 D1 DE 60005471D1
Authority
DE
Germany
Prior art keywords
osteoporosis
treatment
selective agonists
receptor selective
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60005471T
Other languages
English (en)
Other versions
DE60005471T2 (de
Inventor
Kimberly O'keefe Cameron
Hauzhu Ke
Bruce Allen Lefker
David Duane Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60005471D1 publication Critical patent/DE60005471D1/de
Publication of DE60005471T2 publication Critical patent/DE60005471T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE60005471T 1999-12-22 2000-12-11 EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose Expired - Fee Related DE60005471T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17135399P 1999-12-22 1999-12-22
US171353P 1999-12-22

Publications (2)

Publication Number Publication Date
DE60005471D1 true DE60005471D1 (de) 2003-10-30
DE60005471T2 DE60005471T2 (de) 2004-04-22

Family

ID=22623430

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60005471T Expired - Fee Related DE60005471T2 (de) 1999-12-22 2000-12-11 EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose

Country Status (36)

Country Link
US (2) US6737437B2 (de)
EP (1) EP1110949B1 (de)
JP (1) JP2001181210A (de)
KR (1) KR100419681B1 (de)
CN (1) CN1413190A (de)
AP (2) AP2001002357A0 (de)
AT (1) ATE250575T1 (de)
AU (2) AU1293101A (de)
BG (1) BG106882A (de)
BR (1) BR0016560A (de)
CA (1) CA2329678A1 (de)
CO (1) CO5251453A1 (de)
CR (1) CR6678A (de)
CZ (1) CZ20022048A3 (de)
DE (1) DE60005471T2 (de)
DK (1) DK1110949T3 (de)
EA (1) EA005293B1 (de)
EE (1) EE200200355A (de)
ES (1) ES2204458T3 (de)
GE (1) GEP20043203B (de)
HR (1) HRP20020537A2 (de)
HU (1) HUP0005001A3 (de)
IL (1) IL140325A0 (de)
IS (1) IS6388A (de)
MA (1) MA26852A1 (de)
MX (1) MXPA02006322A (de)
NO (1) NO20022925D0 (de)
OA (1) OA12117A (de)
PE (1) PE20010953A1 (de)
PL (1) PL356662A1 (de)
PT (1) PT1110949E (de)
SK (1) SK8552002A3 (de)
TR (2) TR200201643T2 (de)
UA (1) UA72293C2 (de)
WO (1) WO2001046140A1 (de)
ZA (1) ZA200007694B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
CZ20031257A3 (cs) * 2000-11-27 2004-04-14 Pfizer Products Inc. Selektivní agonisty receptoru EP4 při léčení osteoporosy
CN100371322C (zh) 2001-07-16 2008-02-27 霍夫曼-拉罗奇有限公司 作为***素类化合物激动剂的2-吡咯烷酮衍生物
JP2004521954A (ja) * 2001-07-16 2004-07-22 エフ．ホフマン−ラ　ロシュ　アーゲー Ｅｐ４受容体作用薬としてのプロスタグランジン類似体
PT1417975E (pt) * 2001-07-23 2011-05-30 Ono Pharmaceutical Co Medicamentos que cont?m um agonista de ep4 como princ?pio activo destinados a doen?as associadas a perda de massa ?ssea
ES2360604T3 (es) * 2001-07-23 2011-06-07 Ono Pharmaceutical Co., Ltd. Remedios para enfermedades con pérdida de masa osea que tienen como ingrediente activo agonistas de ep4.
WO2003041717A1 (fr) * 2001-11-12 2003-05-22 Ono Pharmaceutical Co., Ltd. Preparation pelliculaire persistante pour administration localisee contenant un derive de prostaglandine
WO2003047417A2 (en) * 2001-12-03 2003-06-12 Merck & Co., Inc. Ep4 receptor agonist, compositions and methods thereof
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
CA2469075C (en) 2001-12-20 2011-09-13 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as prostaglandin modulators
IL163866A0 (en) 2002-03-05 2005-12-18 Ono Pharmaceutical Co 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient
AU2003209571A1 (en) * 2002-03-18 2003-09-29 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
AU2011202937B2 (en) * 2002-05-14 2012-06-07 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
EP1513589B1 (de) 2002-06-06 2010-11-10 Merck Frosst Canada Ltd. 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
CA2483555A1 (en) 2002-06-10 2003-12-18 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
ES2393321T3 (es) 2002-10-10 2012-12-20 Ono Pharmaceutical Co., Ltd. Promotores de la producción de factores de reparación endógenos
EP1581503A4 (de) 2002-11-08 2007-07-25 Merck & Co Inc Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
WO2004063158A1 (en) * 2003-01-10 2004-07-29 F.Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
US7256211B1 (en) 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
DE602004013559D1 (de) 2003-03-03 2008-06-19 Serono Lab G-lactamderivate als prostaglandinagonisten
US6734201B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US6734206B1 (en) 2003-06-02 2004-05-11 Allergan, Inc. 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7179820B2 (en) 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
WO2005012232A2 (en) * 2003-07-18 2005-02-10 Applied Research Systems Ars Holding N.V. Hydrazide derivatives as prostaglandin receptors modulators
JP2007504228A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼組成物
JP4546961B2 (ja) 2003-09-04 2010-09-22 メルク・シャープ・エンド・ドーム・コーポレイション 高眼圧の治療のための眼科用組成物
CA2537430A1 (en) 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2005027931A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
CA2574078A1 (en) 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
AU2005313380A1 (en) 2004-12-06 2006-06-15 Merck Serono Sa Pyrrolidin-2-one derivatives for use as DP1 receptor agonists
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US20090074844A1 (en) 2005-04-28 2009-03-19 Ono Pharmaceutical Co., Ltd. Trenadermal absorption preparation
KR100686186B1 (ko) * 2005-06-13 2007-02-26 영진종합건설 주식회사 교량용 배수 구조물
WO2007017687A2 (en) 2005-08-09 2007-02-15 Asterand Uk Limited Ep2 receptor agonists
EP2085088A4 (de) 2006-10-26 2012-08-29 Ono Pharmaceutical Co Klebende zubereitung
WO2008073748A1 (en) 2006-12-08 2008-06-19 University Of Rochester Expansion of hematopoietic stem cells
EP2220057A4 (de) 2007-11-14 2011-10-12 Cayman Chem Co Prostaglandin-e1- und e2-analoga zur behandlung verschiedener medizinischer leiden
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
US9682065B2 (en) 2011-08-02 2017-06-20 Ono Pharmaceutical Co., Ltd. Left ventricular diastolic function improving agent
CN106748951B (zh) 2012-07-19 2020-07-24 开曼化学股份有限公司 作为在治疗ep4介导的疾病和病状中使用的ep4受体选择性激动剂的二氟内酰胺化合物
WO2014069401A1 (ja) 2012-10-29 2014-05-08 株式会社カルディオ 肺疾患特異的治療剤
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
US9688627B2 (en) * 2013-03-15 2017-06-27 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
KR20160048054A (ko) 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
US9968716B2 (en) 2013-10-15 2018-05-15 Ono Pharmaceutical Co., Ltd. Drug-eluting stent graft
WO2016199111A1 (en) 2015-06-12 2016-12-15 Simon Fraser University Amide-linked ep4 agonist-bisphosphonate compounds and uses thereof
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR897566A (fr) 1942-08-28 1945-03-26 Bopp & Reuther Gmbh Machine à rotors
US3528961A (en) 1966-08-16 1970-09-15 Allied Chem Monoazo dyes from e-caprolactam
US3780095A (en) 1970-04-08 1973-12-18 Byk Gulden Lomberg Chem Fab Acylated anilino-carboxylic acids and their salts
US3987091A (en) 1973-04-12 1976-10-19 Merck & Co., Inc. 11,12-secoprostaglandins
US4033996A (en) 1973-04-25 1977-07-05 Merck & Co., Inc. 8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
SE7414770L (de) 1973-12-13 1975-06-16 Merck & Co Inc
DK366475A (da) 1974-08-30 1976-03-01 Merck & Co Inc Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US3991106A (en) 1974-09-13 1976-11-09 Merck & Co., Inc. 16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en) 1974-09-13 1977-10-25 Merck & Co., Inc. 11,12-Seco-prostaglandins
US4113873A (en) 1975-04-26 1978-09-12 Tanabe Seiyaku Co. Ltd. 8-azaprostanoic acid derivatives
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
IL49325A (en) 1976-03-31 1979-11-30 Labaz 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4175203A (en) 1976-12-17 1979-11-20 Merck & Co., Inc. Interphenylene 11,12-secoprostaglandins
US4243678A (en) 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de) 1980-01-07 1981-07-09 Boehringer Mannheim Gmbh, 6800 Mannheim Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de) 1980-11-11 1982-06-24 A. Nattermann & Cie GmbH, 5000 Köln N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0068968B1 (de) 1981-06-16 1985-09-18 Choay S.A. Arzneimittel als wirksame Substanzverbindungen die den Arylbenzensulfonamid-Typ enthalten und Verfahren zu deren Herstellung
AU6427596A (en) * 1992-04-14 1996-10-31 Alfred Maximillian Stessl A boat hull
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
PT951282E (pt) * 1996-12-20 2008-06-09 Pfizer Prevenção e tratamento de doenças esqueléticas com agonistas e2 de protaglandinas selectivos do subtipo de receptores ep2
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
CA2346038A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for inhibiting bone resorption
AU6427599A (en) * 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation

Also Published As

Publication number Publication date
JP2001181210A (ja) 2001-07-03
US20020040149A1 (en) 2002-04-04
ZA200007694B (en) 2002-06-20
KR100419681B1 (ko) 2004-02-21
IS6388A (is) 2002-05-17
IL140325A0 (en) 2002-02-10
EP1110949A1 (de) 2001-06-27
HUP0005001A2 (hu) 2001-12-28
HUP0005001A3 (en) 2002-01-28
AU1293101A (en) 2001-07-03
SK8552002A3 (en) 2003-09-11
AU7239300A (en) 2001-06-28
KR20010067415A (ko) 2001-07-12
TR200201643T2 (tr) 2002-11-21
ATE250575T1 (de) 2003-10-15
BR0016560A (pt) 2002-09-10
DE60005471T2 (de) 2004-04-22
WO2001046140A1 (en) 2001-06-28
EA005293B1 (ru) 2004-12-30
TR200301841T4 (tr) 2004-01-21
MXPA02006322A (es) 2002-12-13
AP2002002555A0 (en) 2002-06-30
EA200200505A1 (ru) 2002-12-26
AU763983B2 (en) 2003-08-07
CN1413190A (zh) 2003-04-23
EP1110949B1 (de) 2003-09-24
MA26852A1 (fr) 2004-12-20
AP2001002357A0 (en) 2001-12-31
OA12117A (en) 2006-05-04
HU0005001D0 (de) 2001-02-28
BG106882A (en) 2003-02-28
US6737437B2 (en) 2004-05-18
US6642266B2 (en) 2003-11-04
CA2329678A1 (en) 2001-06-22
GEP20043203B (en) 2004-03-25
CR6678A (es) 2004-01-14
CZ20022048A3 (cs) 2004-03-17
DK1110949T3 (da) 2003-11-24
PE20010953A1 (es) 2001-09-25
HRP20020537A2 (en) 2004-12-31
UA72293C2 (en) 2005-02-15
PT1110949E (pt) 2003-12-31
EE200200355A (et) 2003-10-15
NO20022925L (no) 2002-06-18
CO5251453A1 (es) 2003-02-28
NO20022925D0 (no) 2002-06-18
PL356662A1 (en) 2004-06-28
ES2204458T3 (es) 2004-05-01
US20010047105A1 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
ATE250575T1 (de) Ep4 rezeptor selektive agonisten zur behandlung der osteoporose
NO20032360D0 (no) EP4 reseptor selektive agonister for behandling av osteoporose
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE60138129D1 (de) Apparat zur behandlung von zähnen
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
NO20022105D0 (no) Positive modulatorer av nikotinreseptoragonister
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE69819515D1 (de) Hydroxy-prostaglandinderivaten zur behandlung der erektilen dysfunktion
ATE370728T1 (de) Antagonisten des gardos-kanals
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
ATE358483T1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
DE60012554D1 (de) Beta-agonisten zur behandlung der endometriose bzw. unfruchtbarkeit oder steigerung der fruchtbarkeit
NO20022142L (no) Anvendelse av dopamin-D3 reseptor agonister for behandling av saltavhengig hypertensjon
FI5227U1 (fi) Laitteisto laastin jakelemiseksi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee